N-[[1-(3-methoxypropyl)indol-3-yl]methyl]propan-2-amine | 900156-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[[1-(3-methoxypropyl)indol-3-yl]methyl]propan-2-amine
• CAS: 900156-25-4
• 化学式: C₁₆H₂₄N₂O
• 分子量: 260.379
• InChiKey: MWGVIDROCQOTAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(3-methoxypropyl)-1H-indole-3-carbaldehyde 、 异丙胺 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 N-[[1-(3-methoxypropyl)indol-3-yl]methyl]propan-2-amine
  参考文献：
  名称：

  WO2007/77005

  摘要：

  公开号：

文献信息

• Organic Compounds
  申请人：Nihonyanagi Atsuko

  公开号：US20080242662A1

  公开（公告）日：2008-10-02

  The invention relates to substituted 3,4- or higher substituted piperazine compounds, the use thereof for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; pharmaceutical formulations or products comprising said compounds, and/or a method of treatment comprising administering said compounds, a method for the manufacture of said compounds as well as novel intermediates, starting materials and/or partial steps for their synthesis. The compounds are especially of the formula I, wherein R1, R2, R11, C, E and D are as defined in the specification.

  本发明涉及取代的3,4-或更高取代的哌嗪化合物，其用于制备治疗依赖于肾素活性的疾病的药物配方；该类化合物在治疗依赖于肾素活性的疾病中的应用；这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；包括上述化合物和/或其制剂的制药制剂或产品，以及包括给予上述化合物的治疗方法，制造上述化合物的方法以及新的中间体，起始材料和/或其合成的部分步骤。这些化合物特别是公式I，其中R1、R2、R11、C、E和D如规范中所定义。
• 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES
  申请人：Masuya Keiichi

  公开号：US20100029647A1

  公开（公告）日：2010-02-04

  3,4(,5)-substituted tetrahydropyridine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4(,5)-substituted tetrahydropyridine compound, and/or a method of treatment comprising administering a 3,4(,5)-substituted tetrahydropyridine compound, a method for the manufacture of a 3,4(,5)-substituted tetrahydropyridine compound, and novel intermediates and partial steps for its synthesis. The 3,4(,5)-substituted tetrahydropyridine compounds have the formula I wherein the substituents and symbols are as described in the specification.

  3,4(,5)-取代四氢吡啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病；该类化合物用于制备治疗依赖于肾素活性疾病的制药配方；该类化合物用于治疗依赖于肾素活性的疾病；包含3,4(,5)-取代四氢吡啶化合物的制药配方，和/或包括给予3,4(,5)-取代四氢吡啶化合物的治疗方法，以及制备3,4(,5)-取代四氢吡啶化合物的方法，以及其合成的新中间体和部分步骤。3,4(,5)-取代四氢吡啶化合物的化学式为I，其中取代基和符号如说明书所述。
• MORPHOLINE DERIVATIVE
  申请人：Akatsuka Hidenori

  公开号：US20100240644A1

  公开（公告）日：2010-09-23

  The present invention provides a morpholine derivative of the formula [I]; wherein R 1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R 2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R 3 , R 4 , R 5 and R 6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.

  本发明提供了公式[I]的吗啡啶衍生物；其中R1是取代的烷基，可选取代的芳基，可选取代的杂环基，环烷基或烷基；R2是取代的烷基，可选取代的芳基，可选取代的杂环基，可选取代的烷基羰基，可选取代的芳基羰基，可选取代的杂环取代羰基或环烷基羰基；T是亚甲基或羰基；R3，R4，R5和R6相同或不同，是氢原子，可选取代的氨基甲酰基或可选取代的烷基；或其药学上可接受的盐。这些化合物可用作肾素抑制剂。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• US8129411B2
  申请人：——

  公开号：US8129411B2

  公开（公告）日：2012-03-06